Crossmark

Upconversion mesoporous silica nanoparticles co-delivering celecoxib and rose bengal enable multimodal immunogenic and anti-angiogenic therapy for spinal metastasis of non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1038/s41388-026-03679-y

Published Online: 2026-02-11

Published Print: 2026-03-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Xinxin

Liu, Shuangmei

Wang, Ruoyu https://orcid.org/0000-0003-3570-1811
Wang, Xinlei https://orcid.org/0009-0000-7143-5552
Funding

Funding for this research was provided by:

This study was supported by the Revitalizing Liaoning Talents Program-Medical Experts Project (No. YXMJ-JC-10).
License Information

Text and Data Mining valid from 2026-02-11

Version of Record valid from 2026-02-11
More Information

Article History

Received: 3 August 2025

Revised: 10 December 2025

Accepted: 15 January 2026

First Online: 11 February 2026

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below